^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Cutaneous Melanoma |
| Drug: | Imlygic (talimogene laherparepvec) (GM-CSF agonist) |
| Drug Class: | PD1 inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Published date:
02/19/2021
Excerpt:
Melanoma: Cutaneous...NCCN Panel voted not to include combination therapy with T-VEC plus systemic anti-PD-1 therapy as a recommended option...
Secondary therapy:
talimogene laherparepvec
